Blaize (BZAI) Q1 2025 earnings summary

Executive summary

• Transitioned from pilot programs to real-world deployments, with production AI chips and systems shipped to smart city and defense sectors in Q1 2025.

• Completed a reverse recapitalization merger with BurTech Acquisition Corp. in January 2025, resulting in a public listing and significant changes to capital structure.

• Achieved strong commercial momentum, converting pipeline into execution in U.S. defense, South Korea, and Gulf markets, including selection for South Korea's Chungbuk Digital Innovation Hub and advanced defense commercialization with Turbo Federal.

• Announced development of a turnkey vertical AI solution stack to accelerate deployment and reduce customer integration time by up to 50%.

• Dual go-to-market strategy: direct engagement with high-value customers and scaling through channel partners with vertical-ready offerings.

Financial highlights

• Q1 2025 revenue exceeded $1 million, up 83% year-over-year from $0.5 million in Q1 2024, driven by shipments to smart city customers.

• GAAP net loss was $147.8 million, including $226 million in non-cash fair value changes of convertible notes/warrants, partially offset by a $116.5 million credit for earn-out liability, and higher operating expenses.

• Adjusted EBITDA loss was $15.4 million, compared to $7.5 million in Q1 2024.

• Cash and cash equivalents were $45 million as of March 31, 2025.

• Operating loss for Q1 2025 was $38 million.

Outlook and guidance

• Q2 2025 revenue projected at $1.5–$1.7 million; adjusted EBITDA loss expected between $13–$14 million.

• Full-year 2025 revenue guidance reaffirmed at $19–$50 million; adjusted EBITDA loss projected at $40–$55 million.

• Cash runway expected to extend into the first half of 2026, with measures in place to reduce cash burn if needed.

• Management expects continued increases in research and development to support next-generation product development.

• Substantial doubt exists about the ability to continue as a going concern without additional financing.